Total Payments
$178,553
2024 Payments
$32.88
Companies
14
Transactions
238
Medicare Patients
669
Medicare Billing
$43,347
Payment Breakdown by Category
Other$130,491 (73.1%)
Consulting$37,483 (21.0%)
Travel$5,118 (2.9%)
Food & Beverage$4,643 (2.6%)
Education$817.44 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $128,491 | 58 | 72.0% |
| Consulting Fee | $37,483 | 10 | 21.0% |
| Travel and Lodging | $5,118 | 19 | 2.9% |
| Food and Beverage | $4,643 | 138 | 2.6% |
| Grant | $2,000 | 1 | 1.1% |
| Education | $817.44 | 12 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $57,086 | 55 | $0 (2019) |
| Biogen, Inc. | $55,066 | 86 | $0 (2021) |
| EMD Serono, Inc. | $36,926 | 43 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $23,072 | 25 | $0 (2018) |
| Genentech USA, Inc. | $5,743 | 6 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $167.03 | 2 | $0 (2021) |
| Acorda Therapeutics, Inc | $126.48 | 8 | $0 (2019) |
| Mallinckrodt Hospital Products Inc. | $93.88 | 2 | $0 (2022) |
| Celgene Corporation | $88.91 | 5 | $0 (2024) |
| Genentech, Inc. | $76.00 | 2 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $32.88 | 1 | Celgene Corporation ($32.88) |
| 2023 | $63.20 | 2 | TG THERAPEUTICS, INC. ($38.00) |
| 2022 | $136.16 | 8 | Celgene Corporation ($56.03) |
| 2021 | $3,948 | 4 | Biogen, Inc. ($3,875) |
| 2020 | $15,535 | 15 | Biogen, Inc. ($15,454) |
| 2019 | $52,935 | 51 | Biogen, Inc. ($21,502) |
| 2018 | $54,049 | 72 | EMD Serono, Inc. ($14,810) |
| 2017 | $51,853 | 85 | GENZYME CORPORATION ($32,868) |
All Payment Transactions
238 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 03/04/2024 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $32.88 | General |
| Category: Neuroscience | ||||||
| 08/04/2023 | EMD Serono, Inc. | MAVENCLAD (Drug) | Food and Beverage | Cash or cash equivalent | $25.20 | General |
| Category: Neurology | ||||||
| 02/07/2023 | TG THERAPEUTICS, INC. | BRIUMVI (Drug) | Education | In-kind items and services | $38.00 | General |
| Category: Immunology | ||||||
| 12/15/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.21 | General |
| Category: Neuroscience | ||||||
| 12/07/2022 | EMD Serono, Inc. | Mavenclad (Drug) | Food and Beverage | Cash or cash equivalent | $12.22 | General |
| Category: Neurology | ||||||
| 11/03/2022 | Janssen Pharmaceuticals, Inc | Ponvory (Drug) | Food and Beverage | In-kind items and services | $23.36 | General |
| Category: Neuroscience | ||||||
| 09/22/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $13.45 | General |
| Category: Neuroscience | ||||||
| 09/15/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $13.72 | General |
| Category: Neuroscience | ||||||
| 06/16/2022 | Celgene Corporation | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $14.65 | General |
| Category: Neuroscience | ||||||
| 04/04/2022 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Education | In-kind items and services | $29.88 | General |
| Category: IMMUNOLOGY | ||||||
| 02/18/2022 | EMD Serono, Inc. | — | Food and Beverage | Cash or cash equivalent | $14.67 | General |
| 08/23/2021 | Lilly USA, LLC | ERBITUX (Drug), CYRAMZA | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: Oncology | ||||||
| 05/26/2021 | Novartis Pharmaceuticals Corporation | KESIMPTA (Drug) | Food and Beverage | In-kind items and services | $59.03 | General |
| Category: NEUROSCIENCE | ||||||
| 04/29/2021 | Biogen, Inc. | TYSABRI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,395.00 | General |
| Category: NEUROLOGY | ||||||
| 04/22/2021 | Biogen, Inc. | VUMERITY (Drug) | Consulting Fee | Cash or cash equivalent | $2,480.00 | General |
| Category: NEUROLOGY | ||||||
| 12/14/2020 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Education | In-kind items and services | $64.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/09/2020 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,800.00 | General |
| Category: NEUROLOGY | ||||||
| 11/12/2020 | Biogen, Inc. | VUMERITY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| Category: NEUROLOGY | ||||||
| 08/06/2020 | Biogen, Inc. | TECFIDERA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| Category: NEUROLOGY | ||||||
| 07/23/2020 | EMD Serono, Inc. | Mavenclad (Drug) | Food and Beverage | In-kind items and services | $16.87 | General |
| Category: Neurology | ||||||
| 02/28/2020 | Biogen, Inc. | TYSABRI (Biological), TECFIDERA | Food and Beverage | In-kind items and services | $7.17 | General |
| Category: NEUROLOGY | ||||||
| 02/20/2020 | Biogen, Inc. | TECFIDERA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: NEUROLOGY | ||||||
| 02/20/2020 | Biogen, Inc. | TECFIDERA (Drug) | Food and Beverage | In-kind items and services | $40.40 | General |
| Category: NEUROLOGY | ||||||
| 01/11/2020 | Biogen, Inc. | TYSABRI (Biological), TECFIDERA | Consulting Fee | Cash or cash equivalent | $4,387.50 | General |
| Category: NEUROLOGY | ||||||
| 01/11/2020 | Biogen, Inc. | TYSABRI (Biological), TECFIDERA | Travel and Lodging | Cash or cash equivalent | $666.30 | General |
| Category: NEUROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 195 | 246 | $68,671 | $12,755 |
| 2022 | 4 | 186 | 245 | $57,096 | $13,378 |
| 2021 | 2 | 123 | 173 | $26,312 | $8,270 |
| 2020 | 6 | 165 | 219 | $35,951 | $8,943 |
Total Patients
669
Total Services
883
Medicare Billing
$43,347
Procedure Codes
24
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 49 | 58 | $20,880 | $3,536 | 16.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 39 | 47 | $16,920 | $2,814 | 16.6% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 20 | 24 | $6,216 | $1,486 | 23.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 23 | 25 | $6,125 | $1,109 | 18.1% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 14 | 28 | $3,948 | $1,089 | 27.6% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2023 | 20 | 31 | $5,177 | $1,019 | 19.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 19 | 22 | $5,390 | $987.41 | 18.3% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 11 | 11 | $4,015 | $714.78 | 17.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 49 | 60 | $17,221 | $4,347 | 25.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 50 | 57 | $10,477 | $2,681 | 25.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 33 | 42 | $12,100 | $2,513 | 20.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 26 | 37 | $6,994 | $1,647 | 23.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 12 | 21 | $5,340 | $1,179 | 22.1% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Facility | 2022 | 16 | 28 | $4,964 | $1,011 | 20.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 65 | 85 | $11,560 | $3,984 | 34.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 44 | 63 | $8,568 | $2,860 | 33.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 25 | $6,184 | $1,426 | 23.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 23 | 58 | $14,530 | $3,280 | 22.6% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 43 | 52 | $7,072 | $1,864 | 26.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 21 | 21 | $4,389 | $1,348 | 30.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 22 | 24 | $2,694 | $951.49 | 35.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 24 | 26 | $3,536 | $820.88 | 23.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 11 | 11 | $2,299 | $402.15 | 17.5% |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m servic | Office | 2020 | 21 | 27 | $1,431 | $276.11 | 19.3% |
About Dr. Gary Thomas, MD
Dr. Gary Thomas, MD is a Neurology healthcare provider based in Hershey, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1912955907.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gary Thomas, MD has received a total of $178,553 in payments from pharmaceutical and medical device companies, with $32.88 received in 2024. These payments were reported across 238 transactions from 14 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($128,491).
As a Medicare-enrolled provider, Thomas has provided services to 669 Medicare beneficiaries, totaling 883 services with total Medicare billing of $43,347. Data is available for 4 years (2020–2023), covering 24 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Location Hershey, PA
- Active Since 05/04/2006
- Last Updated 01/22/2010
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1912955907
Products in Payments
- AUBAGIO (Drug) $49,513
- COPAXONE (Drug) $22,710
- Rebif (Biological) $21,587
- TECFIDERA (Drug) $18,712
- Mavenclad (Biological) $15,269
- TYSABRI (Biological) $15,107
- VUMERITY (Drug) $6,530
- OCREVUS (Biological) $5,819
- LEMTRADA (Drug) $5,569
- MS DISEASE STATE (Drug) $2,004
- GILENYA (Drug) $108.00
- ACTHAR (Biological) $93.88
- AMPYRA (Drug) $90.22
- ZEPOSIA (Drug) $88.91
- KESIMPTA (Drug) $59.03
- BRIUMVI (Drug) $38.00
- INBRIJA (Drug) $36.26
- Betaseron (Drug) $32.55
- Mavenclad (Drug) $29.09
- MAVENCLAD (Drug) $25.20
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Hershey
Thyagarajan Subramanian, Md, MD
Neurology — Payments: $390,061
Neurology $390,061
Dr. Sol De Jesus, M.d, M.D
Neurology — Payments: $126,431
Neurology $126,431
Dr. Donald Dworek, D.o, D.O
Neurology — Payments: $38,455
Neurology $38,455
Dr. James Grogan, M.d, M.D
Neurology — Payments: $25,160
Neurology $25,160
Alain Zingraff Lekoubou Looti, Md, MD
Neurology — Payments: $20,864
Neurology $20,864
Dr. Venkata Jakkampudi, M.d, M.D
Neurology — Payments: $8,334
Neurology $8,334